Arimidex tablets are taken by mouth for hormone-sensitive breast cancer, mainly after menopause. The active ingredient, anastrozole, lowers oestrogen production by blocking aromatase, helping reduce…
Arimidex tablets are taken by mouth for hormone-sensitive breast cancer, mainly after menopause. The active ingredient, anastrozole, lowers oestrogen production by blocking aromatase, helping reduce hormonal stimulation of certain breast-cancer cells.
Arimidex contains anastrozole, a non-steroidal aromatase inhibitor supplied as oral tablets. It is used in endocrine treatment for hormone receptor-positive breast cancer in postmenopausal women.
Arimidex contains anastrozole, a non-steroidal aromatase inhibitor supplied as oral tablets. It is used in endocrine treatment for hormone receptor-positive breast cancer in postmenopausal women. Doctors may prescribe it after surgery, after other endocrine treatment, or for advanced disease, depending on the tumour profile and treatment plan [1].
The medicine is mainly intended for women who have reached menopause. After menopause, the ovaries produce much less oestrogen, but tissues such as fat, muscle, and breast tissue can still make small amounts through aromatase activity. Anastrozole reduces this peripheral production.
Premenopausal women still produce substantial ovarian oestrogen. Arimidex alone is therefore not generally suitable for routine endocrine treatment before menopause. In selected cases, a specialist may combine an aromatase inhibitor with ovarian suppression, but that is a different treatment plan requiring oncology supervision.
Arimidex may be used for:
The tablet is swallowed and taken at a regular time. Treatment duration varies because cancer stage, recurrence risk, previous endocrine therapy, bone health, and tolerance all influence the decision.
Arimidex is not used to treat every type of breast cancer. Its benefit depends on hormone receptor status and the broader clinical picture, including HER2 status, tumour stage, lymph-node involvement, and menopausal state.
Arimidex contains anastrozole, a non-steroidal aromatase inhibitor supplied as oral tablets. Anastrozole lowers oestrogen production by blocking aromatase. The medicine is used in endocrine treatment for hormone receptor-positive breast cancer in postmenopausal women.
Anastrozole inhibits aromatase, the enzyme that converts androgen hormones into oestrogens. The pathway includes conversion of androstenedione into oestrone and conversion of testosterone-related substrates into oestradiol. Blocking this enzyme lowers circulating oestradiol and oestrone concentrations.
The effect is hormonal rather than cytotoxic. Arimidex does not directly destroy cancer cells in the way a chemotherapy agent may. It removes an oestrogen signal that can encourage hormone-sensitive breast-cancer cells to grow.
Aromatase belongs to the cytochrome P450 enzyme family. In postmenopausal patients, it is a major source of oestrogen production outside the ovaries. Anastrozole binds to the aromatase enzyme and suppresses its activity, reducing the conversion of androgen precursors into oestradiol and estrone.
That distinction explains why menopausal status matters. A premenopausal ovary can continue producing oestrogen even when peripheral aromatase activity is reduced. Ovarian suppression may therefore be required before an aromatase inhibitor can provide the intended endocrine effect.
The European Medicines Agency describes anastrozole as a potent and selective non-steroidal aromatase inhibitor. The FDA prescribing information also identifies suppression of oestrogen synthesis as the central pharmacological action [2].
Arimidex differs from tamoxifen by acting on hormone production rather than mainly blocking oestrogen receptors in breast tissue. Letrozole is another non-steroidal aromatase inhibitor. Exemestane works through irreversible aromatase inactivation and belongs to a different chemical subgroup.
Arimidex tablets are taken orally once daily at the prescribed dose. The tablet should be swallowed with water and taken at approximately the same time each day. It can generally be taken with or without food.
The correct amount differs between strengths and between users, so there is no single dose that suits everyone. The oncology team selects the regimen according to the indication, treatment history, liver function, tolerability, and planned duration.
A common mistake is stopping after several uncomfortable weeks without discussing alternatives. Aromatase-inhibitor symptoms can sometimes be managed through exercise, analgesia, a treatment switch, or a planned break decided by the cancer team. Stopping independently can interrupt the endocrine strategy.
Another overlooked detail is the timing of bone monitoring. A baseline fracture-risk assessment may be needed before treatment, followed by repeat bone-density testing when clinically appropriate.
The choice depends on menopausal status, recurrence risk, previous therapy, bone health, blood-clot risk, and adverse effects. The active ingredients below are generic names rather than product-brand comparisons.
| Treatment approach | Main action | Clinical distinction |
|---|---|---|
| Anastrozole | Blocks aromatase and lowers oestrogen production | Commonly used after menopause |
| Letrozole or exemestane | Suppress aromatase through different molecular structures | Alternatives within aromatase-inhibitor therapy |
| Tamoxifen | Modulates oestrogen receptors in breast tissue | May be used before menopause or when an aromatase inhibitor is unsuitable |
Anastrozole, letrozole, and exemestane can all cause joint symptoms and bone loss because they reduce oestrogen activity. One agent may be better tolerated than another for a particular patient, so a switch can sometimes preserve endocrine benefit while improving day-to-day function.
Tamoxifen has a different risk pattern. It can be useful before menopause and may be preferred when bone density is a major concern. It also carries risks such as venous thromboembolism and endometrial changes, which need individual assessment.
Generic anastrozole has the same active ingredient as Arimidex. The clinical decision concerns the active ingredient, formulation, treatment plan, and patient response rather than the name alone.
Several patterns repeatedly make endocrine treatment harder to continue:
One practical point is easy to miss: a missed dose should not be “repaired” with two tablets. Excess dosing does not restore the missed treatment interval and may increase adverse effects.
Another is record keeping. A calendar, medication log, or reminder can reduce missed doses, especially when endocrine treatment continues for several years.
Arimidex is not suitable for everyone. This medication is not for you if you have a confirmed allergy to anastrozole or any tablet ingredient, or if you are pregnant or breastfeeding. It is also not routinely appropriate before menopause unless a specialist has established ovarian suppression as part of the treatment plan.
Tell the treating team before therapy if you have:
Oestrogen-containing medicines may counteract the intended effect of anastrozole because they replace the hormone the treatment is designed to reduce. This includes some hormone therapies and selected products used for menopausal symptoms.
Tamoxifen may reduce anastrozole plasma concentrations and can interfere with its intended pharmacological effect when taken concurrently. Sequential treatment can be clinically appropriate, but the transition needs a defined plan. Do not overlap or switch between endocrine therapies without the oncology team’s instruction.
The WHO describes endocrine therapy as a central treatment strategy for hormone-sensitive breast cancer, with selection guided by tumour biology, menopausal status, and the person’s wider health [4].
This medication is not for you if you have a confirmed allergy to anastrozole or any tablet ingredient, or if you are pregnant or breastfeeding. It is also not routinely appropriate before menopause unless a specialist has established ovarian suppression as part of the treatment plan.
Lowering oestrogen can produce symptoms throughout the body. The most frequently reported problems include hot flushes, sweating, reduced energy, headache, nausea, sleep disturbance, joint pain, muscle pain, and stiffness. These effects vary widely.
Arthralgia means joint pain. It may affect the hands, wrists, knees, hips, ankles, or shoulders. Some patients describe stiffness on waking, while others notice pain after resting. The symptom can be mild, but persistent pain deserves review because another joint condition may be present.
Oestrogen helps maintain bone remodelling balance. Long-term suppression may reduce bone mineral density and increase the risk of osteopenia, osteoporosis, and fractures. The risk is higher in people with a previous fracture, low body weight, smoking history, limited physical activity, or other medicines that weaken bone.
Possible monitoring may include:
Hot flushes may occur during the day or at night. Loose layers, a cooler bedroom, and avoiding individual triggers such as alcohol or very hot drinks can help some people. Menopausal hormone therapy is generally unsuitable for hormone-sensitive breast cancer unless the oncology team specifically directs otherwise.
Mood changes, low mood, anxiety, and depression can occur. Severe or rapidly worsening depression, thoughts of self-harm, or marked behavioural change require urgent medical attention.
The MHRA recognises musculoskeletal symptoms and bone effects as clinically relevant concerns with aromatase inhibitors. The same regulatory information supports monitoring and individual assessment rather than stopping treatment automatically [3].
In clinical practice, oncologists usually frame Arimidex as long-term risk-reduction or disease-control treatment rather than a tablet expected to produce an immediate sensation. The value is assessed through the cancer plan, follow-up examinations, imaging when indicated, and adherence over time.
Doctors often ask about joint symptoms in practical terms: whether the patient can climb stairs, grip objects, sleep, walk, or work comfortably. This is more useful than rating pain with a single number.
A specialist may investigate other explanations for fatigue or pain, including thyroid disease, vitamin deficiency, inflammatory arthritis, reduced activity, or another medicine. A treatment change can be considered when adverse effects threaten adherence.
The National Institute for Health and Care Excellence supports shared decisions around adjuvant endocrine treatment, taking recurrence benefit and tolerability into account. The treatment may be adjusted, but the decision should preserve the intended cancer-care strategy.
Pregnancy rules out Arimidex because anastrozole reduces oestrogen activity and may harm a developing pregnancy. The EMA product information identifies pregnancy and breastfeeding as situations in which anastrozole should not be used. A confirmed allergy to anastrozole or a tablet ingredient is another clear reason to avoid it. Menopausal status also matters because Arimidex alone is generally not suitable for women who are still producing ovarian oestrogen; this remains the position reflected in EMA information from 2025.
Seek urgent medical assessment for breathing difficulty, facial or throat swelling, fainting, severe chest pain, sudden weakness, or symptoms of a serious allergic reaction. A new fracture, severe back pain, sudden leg swelling, or unexplained vaginal bleeding also needs prompt review. The MHRA's 2025 safety framework for endocrine therapy supports rapid assessment of serious or unexpected symptoms rather than assuming they are routine treatment effects. The treating team can help distinguish expected treatment effects from symptoms requiring urgent care. Severe depression or thoughts of self-harm require urgent mental-health support and immediate contact with the treating team.
Joint pain and stiffness are recognised effects of aromatase-inhibitor treatment. The FDA prescribing information for anastrozole identifies musculoskeletal symptoms among reported adverse reactions, with severity ranging from mild discomfort to symptoms that affect mobility. Pain may improve with movement, physiotherapy, or a change in endocrine treatment, but that decision belongs to the oncology team. Swelling, redness, marked weakness, or pain after injury suggests a separate assessment is needed; this information is consistent with FDA safety material available in 2025.
Arimidex is not usually classified as a sedative, but fatigue, dizziness, sleep disruption, pain, or visual symptoms may affect driving and concentration. The MHRA advises patients to understand how a medicine affects them before driving or operating machinery. Avoid these activities if you feel dizzy, unusually tired, or unable to concentrate properly. A 2025 MHRA medicines-safety approach supports individual assessment because the same tablet can affect daily function differently from one person to another.
The best time is one that supports consistent daily dosing and fits the prescribed schedule. Some people choose breakfast, while others prefer evening dosing if daytime symptoms are troublesome. The EMA product information allows oral administration without a food-dependent timing requirement. Changing the time is reasonable only when it does not disrupt adherence and the treating team agrees; EMA information current in 2025 supports regular daily administration rather than a universally required clock time.
Arimidex should not be used during pregnancy or breastfeeding. Anastrozole lowers oestrogen activity and is intended for endocrine treatment in appropriate cancer settings, not for use during fetal development or lactation. The WHO and EMA recognise pregnancy and breastfeeding as clinically important restrictions for endocrine medicines of this type. Contraception and treatment timing should be discussed with the oncology team before therapy, with EMA product information from 2025 providing the relevant regulatory basis.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 5 reviews
I had been taking anastrozole for about four months when my fingers became stiff in the morning. Walking before breakfast helped, and my oncology nurse arranged a review rather than telling me to stop. The flushes were still irritating, but they became less frequent.
Hull About four months 22 Oct 2026After six weeks I felt more tired and had aching knees after sitting at my desk. My treatment team changed the timing and checked my general health. The tablets were easy to take, although I needed a reminder because I sometimes forgot them at weekends.
Manchester Six weeks 28 Oct 2026I used Arimidex after surgery and remained consistent for more than a year. My bone-density assessment made the treatment feel more structured. The main drawback was hand and wrist pain, which improved after regular strengthening exercises.
Nottingham More than a year 30 Sept 2026The first two months were difficult because of night sweats and poor sleep. I did not notice a quick change in how I felt, which was frustrating. My doctor explained that the treatment goal was reducing hormone stimulation, not producing an immediate symptom.
Bournemouth The first two months 6 Oct 2026I stopped taking the tablets for several days because my hip pain worried me. The cancer team wanted to know about it and arranged further assessment. A different endocrine plan was discussed, and I learned that stopping without reporting symptoms can make treatment planning harder.
Luton Several days 13 Oct 2026
